A Phase 2a Study of ALXN1007 in Subjects With Newly Diagnosed Acute Graft-versus-Host Disease Involving the Lower Gastrointestinal Tract
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
Price : $35 *
At a glance
- Drugs Olendalizumab (Primary)
- Indications Graft-versus-host disease
- Focus Proof of concept; Therapeutic Use
- Acronyms GIGVHD
- Sponsors Alexion Pharmaceuticals
- 15 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 27 Feb 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Feb 2017.
- 27 Feb 2017 Status changed from recruiting to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History